{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:21:56Z","timestamp":1760170916007,"version":"3.40.5"},"reference-count":42,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jpsychores.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Psychosomatic Research"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.jpsychores.2015.06.003","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T12:35:55Z","timestamp":1434630955000},"page":"640-645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Psychomotor retardation and vulnerability to interferon alpha induced major depressive disorder: Prospective study of a chronic hepatitis C cohort"],"prefix":"10.1016","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0478-7296","authenticated-orcid":false,"given":"Richard","family":"Whale","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renata","family":"Fialho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Rolt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Eccles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Majella","family":"Keller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"File","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inam","family":"Haq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeremy","family":"Tibble","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpsychores.2015.06.003_bb0005","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0010","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alpha 2-b plus ribavirin compared with interferon alpha 2-a plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0015","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1136\/jnnp-2011-301779","article-title":"Depression: an inflammatory illness?","volume":"83","author":"Krishnadas","year":"2012","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0020","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.4088\/JCP.12r07694","article-title":"Interferon induced depression in chronic hepatitis C: a systematic review and meta-analysis","volume":"73","author":"Udina","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0025","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/sj.npp.1301029","article-title":"The proinflammatory cytokines interleukin-1b and tumor necrosis factor-alpha activate serotonin transporters","volume":"31","author":"Zhu","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0030","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.biopsych.2008.11.029","article-title":"Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression","volume":"65","author":"Miller","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0035","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bbi.2013.04.003","article-title":"Tryptophan metabolism and immunogenetics in major depression: a role for interferon-\u03b3 gene","volume":"31","author":"Myint","year":"2013","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1017\/S0033291713001062","article-title":"Effect of interferon-\u03b1 on cortical glutamate in patients with hepatitis C: a proton magnetic resonance spectroscopy study","volume":"44","author":"Taylor","year":"2014","journal-title":"Psychol Med"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0045","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/mp.2008.58","article-title":"Interferon-alpha effects on diurnal hypothalamic\u2013pituitary\u2013adrenal axis activity: relationship with proinflammatory cytokines and behavior","volume":"15","author":"Raison","year":"2010","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0050","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.neulet.2012.02.087","article-title":"5HT (1-A) receptor and apoptosis contribute to interferon alpha induced \u2018depression-like\u2019 behaviour in mice","volume":"514","author":"Ping","year":"2012","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0055","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1176\/appi.ajp.157.6.867","article-title":"Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review","volume":"157","author":"Dieperink","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0060","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0022-3999(00)00155-0","article-title":"Depression, fatigue, and functional disability in patients with chronic hepatitis C","volume":"49","author":"Dwight","year":"2000","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0065","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/sj.mp.4001119","article-title":"A prospective study of the incidence and open-label treatment of interferon induced major depressive disorder in patients with hepatitis C","volume":"7","author":"Hauser","year":"2002","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0070","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0163-8343(02)00239-6","article-title":"Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study","volume":"25","author":"Horikawa","year":"2003","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0075","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.biopsych.2009.11.005","article-title":"Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulation polyunsaturated fatty acids levels","volume":"67","author":"Su","year":"2010","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0080","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.biopsych.2008.08.009","article-title":"Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism","volume":"65","author":"Lotrich","year":"2009","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0085","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.euroneuro.2012.03.009","article-title":"Pre treatment waking cortisol response and vulnerability to interferon alpha induced depression","volume":"22","author":"Eccles","year":"2012","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0090","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1002\/hep.23699","article-title":"Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C","volume":"52","author":"Leutscher","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0095","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/S0893-133X(01)00407-9","article-title":"Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions","volume":"26","author":"Capuron","year":"2002","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0100","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1038\/npp.2011.330","article-title":"Neurobehavioral effects of interferon-\u03b1 in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine","volume":"37","author":"McNutt","year":"2012","journal-title":"Neuropsychopharmacology"},{"year":"1996","series-title":"Structured clinical interview for DSM-IV Axis I disorders, clinician version (SCID-CV)","author":"First","key":"10.1016\/j.jpsychores.2015.06.003_bb0105"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0115","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4088\/JCP.08m04230","article-title":"Pegylated interferon and ribavirin induced depression in chronic hepatitis C: a role of personality","volume":"70","author":"Castellvi","year":"2009","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0120","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1176\/ajp.156.7.1120","article-title":"Depression from interferon therapy in patients with hepatitis C","volume":"156","author":"Miyaoka","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0125","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00023210-200519020-00002","article-title":"Neuropsychiatric adverse effects of interferon-alpha: recognition and management","volume":"19","author":"Raison","year":"2005","journal-title":"CNS Drugs"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0130","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jpsychores.2014.05.008","article-title":"Role of baseline depressive symptoms in the development of depressive episode in patients receiving antiviral therapy for hepatitis C infection","volume":"77","author":"Mahajan","year":"2014","journal-title":"J Psychosom Res"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0135","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.biopsych.2007.12.007","article-title":"Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans","volume":"63","author":"Brydon","year":"2008","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0140","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1600-0404.1999.tb00721.x","article-title":"Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism","volume":"100","author":"Dobbs","year":"1999","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0145","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2004.02.002","article-title":"Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses","volume":"40","author":"Hultgren","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0150","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.pnpbp.2010.06.014","article-title":"Depression is an inflammatory disease, but cell-mediated immune activation is the key component of depression","volume":"35","author":"Maes","year":"2011","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0155","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbi.2010.10.008","article-title":"Immune suppression and immune activation in depression","volume":"25","author":"Blume","year":"2011","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.genhosppsych.2015.03.016","article-title":"Genotype 1 of hepatitis C virus increases the risk of major depression: a 12-week prospective study","author":"Cunha","year":"2015","journal-title":"Gen Hosp Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0165","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.psychres.2009.02.011","article-title":"Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment","volume":"177","author":"Franzen","year":"2010","journal-title":"Psychiatry Res"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0170","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.bbi.2009.07.001","article-title":"Cytokine-induced depression during IFN-alpha treatment: the role of IL-6 and sleep quality","volume":"23","author":"Prather","year":"2009","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0175","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1097\/JCP.0b013e31825d9982","article-title":"Symptomatic treatment of interferon-\u03b1-induced depression in hepatitis C: a systematic review","volume":"32","author":"Baraldi","year":"2012","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0180","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.psym.2013.06.015","article-title":"Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis","volume":"55","author":"Sarkar","year":"2014","journal-title":"Psychosomatics"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0185","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.4088\/JCP.v66n0814","article-title":"Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic\/hypomanic and depressive symptoms","volume":"66","author":"Constant","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0190","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1600-0447.2008.01257.x","article-title":"Long-term antidepressant treatment in bipolar disorder: meta-analyses of benefits and risks","volume":"118","author":"Ghaemi","year":"2008","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0195","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jad.2006.09.017","article-title":"Depression in methadone maintenance treatment patients: rate and risk factors","volume":"99","author":"Peles","year":"2007","journal-title":"J Affect Disord"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0200","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/da.20822","article-title":"Dietary intake of omega-3 fatty acids and risk of depressive symptoms in adolescents","volume":"28","author":"Oddy","year":"2011","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0205","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1586\/17474124.2015.960394","article-title":"Optimizing triple therapy and IFN\/RBV-free regimens for hepatitis C virus infection","volume":"9","author":"Chayama","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jpsychores.2015.06.003_bb0210","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1176\/appi.ajp.2013.12060860","article-title":"Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG screening outcome in psychiatry study","volume":"170","author":"Girardin","year":"2013","journal-title":"Am J Psychiatry"}],"container-title":["Journal of Psychosomatic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022399915004663?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022399915004663?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T15:35:13Z","timestamp":1691768113000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022399915004663"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S0022399915004663"],"URL":"https:\/\/doi.org\/10.1016\/j.jpsychores.2015.06.003","relation":{},"ISSN":["0022-3999"],"issn-type":[{"type":"print","value":"0022-3999"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Psychomotor retardation and vulnerability to interferon alpha induced major depressive disorder: Prospective study of a chronic hepatitis C cohort","name":"articletitle","label":"Article Title"},{"value":"Journal of Psychosomatic Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpsychores.2015.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}